Drugs / A-CAR028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07198867 | Sep 2025 → Dec 2026 expected | acute myeloid leukemia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-CAR028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07198867 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell (CAR-T)” NCT07198867 ↗ |
| Route | Intravenous | “Autologous A-CAR028 administered by intravenous (IV) infusion” NCT07198867 ↗ |
| Target | CD33 | “targeting both CD33 and CLL-1 antigens” NCT07198867 ↗ |